INTRODUCTION AND OBJECTIVES:
Previous studies have demonstrated that the cell cycle progression (CCP) score measured in prostate biopsy specimens was predictive of several clinical outcomes. However, it is currently unclear whether the CCP score improves clinical risk stratification within Gleason score (GS) 6 cancers and the subset of patients with National Comprehensive Cancer Network (NCCN) low-risk disease. Therefore, our objective was to determine the prognostic utility of the CCP score in men with NCCN low-risk disease who underwent radical prostatectomy (RP).
METHODS: Patients who underwent RP for GS 6 prostate cancer at three institutions (Martini Clinic [MC] , Durham Veterans Affairs Medical Center [DVA] , and Intermountain Healthcare [IHC]) were identified. The CCP score was obtained from diagnostic (DVA, IHC) or simulated biopsies (MC). Primary outcome was biochemical recurrence (BCR, PSA0.2 ng/ml) after RP. Prognostic utility of the CCP score was assessed using Kaplan-Meier analysis and multivariable Cox proportional hazards models in the subset of men meeting NCCN low-risk criteria and the overall cohort (all GS 6 prostate cancer patients).
RESULTS: Among the 236 patients identified, 80% (188/236) met NCCN low-risk criteria. Five-year BCR-free survival for the low (<0), intermediate (0-1), and high (>1) CCP score groups was 89.2%, 80.4%, 64.7%, respectively in the low-risk cohort (log-rank p¼0.027), and 85.9%, 79.1%, 63.1% respectively in the overall cohort (log-rank p¼0.041). In multivariable models adjusting for clinical and pathological variables with the CAPRA score, the CCP score was an independent predictor of BCR in the low-risk (HR¼1.77 per unit score, 95%CI [1.21, 2.58], p¼0.003) and overall cohorts (HR¼1.41 per unit score, 95%CI [1.02, 1.96], p¼0.039).
CONCLUSIONS: In a cohort of NCCN low-risk patients, the CCP score improved clinical risk stratification of patients at increased risk of BCR. This suggests the CCP score could help improve the assessment of candidacy for active surveillance and guide optimal treatment selection in patients with NCCN low-risk prostate cancer.
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INTRODUCTION AND OBJECTIVES:
We previously showed that decreased expression of the Lysine-Specific Demethylase 0 KDM5D 0 encoded on the Y chromosome was associated with docetaxel resistance (Komura et al, 2016, PNAS) . We hypothesize that loss of KDM5D may significantly affect the epigenetic landscape in prostate cancer cells and facilitate the development of CRPC.
METHODS: To elucidate biological function of KDM5D, we performed RNAseq analysis in hormone sensitive LNCaP cells (KDM5D positive) and corresponding LNCaP-104R2 CRPC cells (KDM5D negative). Individual genes which were found as potential targets of KDM5D were further explored in a publically available clinical database.
RESULTS: We found 143 overlapping genes, which are upregulated by knockdown of KDM5D in LNCaP and down regulated by overexpression of KDM5D in 104R2 and 28 genes, which were down regulated by KDM5D knockdown in LNCaP and up-regulated by KDM5D overexpression in 104R2. Gene ontology (GO) analyses with FDR<0.05 from the 143 genes identified mitotic and cell cycle related genes as most commonly upregulated by loss of KDM5D (Figure 1) . To validate the results, we explored the Taylor 0 s prostate cancer cohort with cBioportal. Of 8643 genes negatively correlated with KDM5D expression level (Pearson Correlation Coefficient < -0.3), 69 genes were identified in both our data and the Taylor 0 s cohort. Upregulation of these genes in CRPC was further confirmed in 2 publicly available datasets (PAD).2 (Figure 2 ). Finally in a PAD from a Mayo Clinic 0 s cohort (Illumina DASL Cancer Panel microarray) which included 8 genes out of the 69 genes, noted shorter cancer-specific mortality in pts with higher expression of those genes was demonstrated in all 8 genes.
CONCLUSIONS: Loss of KDM5D is associated with upregulation of mitotic and cell-cycle related genes which may lead to development of CRPC and serve as prognostic factor for its development. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e343
